小柯机器人

德国科隆大学Florian Klein研究小组从患者体内分离出新冠病毒（SARS-CoV-2）有效中和抗体。相关论文于2020年7月7日在线发表在《细胞》杂志上。

为了鉴定SARS-CoV-2中和抗体，研究人员分析了确诊后8至69天的12名COVID-19患者抗体反应。通过筛选4313个SARS-CoV-2-反应性B细胞，研究人员在确诊后的第8天开始就从不同时间点分离了255种抗体。其中，有28种能够有效中和SARS-CoV-2（IC100低至0.04μg/ml），并表现出广谱的V基因和低水平的体细胞突变。值得注意的是，研究人员在COVID-19大流行之前从48位健康个体的初始B细胞库中鉴定出了潜在的前体。这些结果表明，SARS-CoV-2中和抗体可从多种前体中轻易产生，从而有望在接种疫苗后迅速诱导保护性免疫应答。

SARS-CoV-2大流行对公共卫生、社会生活和世界经济产生了前所未有的影响。由于无法获得批准的药物和疫苗，用于COVID-19治疗和预防的新选择需求迫在眉睫。

附：英文原文

Title: Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

Author: Christoph Kreer, Matthias Zehner, Timm Weber, Meryem S. Ercanoglu, Lutz Gieselmann, Cornelius Rohde, Sandro Halwe, Michael Korenkov, Philipp Schommers, Kanika Vanshylla, Veronica Di Cristanziano, Hanna Janicki, Reinhild Brinker, Artem Ashurov, Verena Krhling, Alexandra Kupke, Hadas Cohen-Dvashi, Manuel Koch, Jan Mathis Eckert, Simone Lederer, Nico Pfeifer, Timo Wolf, Maria J.G.T. Vehreschild, Clemens Wendtner, Ron Diskin, Henning Gruell, Stephan Becker, Florian Klein

Issue&Volume: 2020-07-07

Abstract: The SARS-CoV-2 pandemic has unprecedented implications for public health, social life, and world economy. Since approved drugs and vaccines are not available, new options for COVID-19 treatment and prevention are highly demanded. To identify SARS-CoV-2 neutralizing antibodies, we analysed the antibody response of 12 COVID-19 patients from 8 to 69 days post diagnosis. By screening 4,313 SARS-CoV-2-reactive B cells, we isolated 255 antibodies from different time points as early as 8 days post diagnosis. Of these, 28 potently neutralized authentic SARS-CoV-2 (IC100 as low as 0.04 μg/ml), showing a broad spectrum of V genes and low levels of somatic mutations. Interestingly, potential precursors were identified in nave B cell repertoires from 48 healthy individuals that were sampled before the COVID-19 pandemic. Our results demonstrate that SARS-CoV-2 neutralizing antibodies are readily generated from a diverse pool of precursors, fostering the hope of rapid induction of a protective immune response upon vaccination.

DOI: 10.1016/j.cell.2020.06.044

Source: https://www.cell.com/cell/fulltext/S0092-8674(20)30821-7